肺癌化疗中培美曲塞的临床效果观察

摘要

Objective:To explore the clinical effect of Pemetrexed in the treatment of advanced non small cell lung cancer(NSCLC),and provide clinical reference for standard first-line,second-line chemotherapy of advanced non small cell lung cancer.Method:The clinical data of 78 patients with Pemetrexed chemotherapy in oncology department of our hospital from June 2009 to June 2014 were retrospectively analyzed,including 33 Initial treatment were given Pemetrexed combined with Cisplatin in the first-line chemotherapy,45 retreatment patients with progress were given Pemetrexed single agent chemotherapy in second-line,and the clinical treatment and clinical effect of the two groups were observed and analyzed.Result:In 33 patients with first-line chemotherapy,the partial remission(PR) in 16 cases,accounting for 48.49%,the stable disease(SD) in 10 cases, accounting for 30.30%,the disease progression(PD) in 7 cases,accounting for 21.21%,the total effective rate of treatment was 48.49% (16/33),the disease control rate was 78.79%(26/33).In 45 patients with second-line chemotherapy,the partial remission (PR) in 6 cases,accounting for 13.33%,the stable disease(SD) in 17 cases,accounting for 37.78%,the disease progression(PD) in 22 cases,accounting for 48.89%,the total effective rate of treatment was 13.33%(6/45),the disease control rate was 51.11%(23/45).Conclusion:The effect of Pemetrexed based chemotherapy in the treatment of advanced non small cell lung cancer is obvious, Pemetrexed with low toxicity,the tolerability and safety are good,it is worth to be in clinical application.%目的：探究培美曲塞在治疗晚期非小细胞肺癌（NSCLC）的临床效果，为晚期非小细胞肺癌的标准一、二线化疗提供临床参考。方法：回顾性分析2009年6月-2014年6月在本院肿瘤科接受培美曲塞化疗78例患者的临床资料，其中33例初治患者采用了培美曲塞联合顺铂方案一线化疗，45例复治进展患者采用了培美曲塞单药二线化疗，对两组患者的临床治疗过程和临床效果进行观察分析。结果：33例一线化疗的患者部分缓解（PR）患者为16例，占48.49%，无变化（SD）患者为10例，占30.30%，疾病进展（PD）患者为7例，占21.21%，治疗的总有效率为48.49%（16/33），疾病控制率为78.79%（26/33）。45例二线化疗的患者部分缓解（PR）患者为6例，占13.33%，无变化（SD）患者为17例，占37.78%，疾病进展（PD）患者为22例，占48.89%，治疗的总有效率为13.33%（6/45），疾病控制率为51.11%（23/45）。结论：培美曲塞为主的化疗治疗晚期非小细胞肺癌效果明显，培美曲塞毒性低，耐受性、安全性好，值得在临床中加以应用。